depatuxizumab mafodotin
mAbexperimentalADC
Depatuxizumab mafodotin is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. — Wikipedia
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01741727)
Timeline
Indications
Studied for
- Burkitt Lymphoma · Phase 1
- Glioblastoma · Phase 3
- Glioma · Phase 1
- Gliosarcoma · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Neoplasms · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Epidermal growth factor receptor erbB1BINDING AGENT
EGFR binding agent
- B-lymphocyte antigen CD19BINDING AGENT
CD19 binding agent
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
EGFR inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Monomethylauristatin F
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDepatuxizumab mafodotin ↗
- ChEMBLCHEMBL3707277 ↗
- ChEMBLCHEMBL3545371 ↗
Also known as
- abt-414
- abt-414
- abt-414
- denintuzumab mafodotin
- denintuzumab mafodotin
- denintuzumab mafodotin
- depatuxizumab mafodotin
- depatuxizumab mafodotin
- sgn-19a
- sgn-cd19a
- sgn-cd19a
- sgn-cd19a
- sgn-cd19b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03419403 | Phase 3 | Jul 19, 2018 | AbbVie |
| NCT03123952 | N/A | Apr 18, 2017 | AbbVie |
| NCT02855359 | Phase 2 | Aug 1, 2016 | Seattle Genetics |
| NCT02702141 | Phase 1 | Feb 1, 2016 | Seattle Genetics |
| NCT02573324 | Phase 2 | Dec 22, 2015 | AbbVie, Radiation Therapy Oncology Group |
| NCT02592876 | Phase 2 | Oct 1, 2015 | Seattle Genetics |
| NCT02590263 | Phase 1 | Sep 7, 2015 | AbbVie |
| NCT02343406 | Phase 2 | Feb 11, 2015 | AbbVie, European Organisation for Research and Treatment of Cancer |
| NCT01800695 | Phase 1 | Apr 2, 2013 | AbbVie |
| NCT01786135 | Phase 1 | Feb 1, 2013 | Seattle Genetics |
| NCT01786096 | Phase 1 | Feb 1, 2013 | Seattle Genetics |
| NCT01741727 | Phase 1 | Oct 1, 2012 | AbbVie |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 7 | 7 | 4 | 2012 |
| Seattle Genetics | For profit | 5 | 5 | 2 | 2013 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Radiation Therapy Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1